Pages that link to "Q33304691"
Jump to navigation
Jump to search
The following pages link to Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer (Q33304691):
Displaying 50 items.
- Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis (Q27001269) (← links)
- DNA copy number alterations and expression of relevant genes in triple-negative breast cancer (Q28271168) (← links)
- The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer (Q33378965) (← links)
- The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study (Q33480671) (← links)
- Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy (Q33573055) (← links)
- Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis (Q33575459) (← links)
- Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype (Q33710233) (← links)
- Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer (Q33851448) (← links)
- Triple-negative breast cancer: role of specific chemotherapy agents (Q33900930) (← links)
- Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer (Q33986198) (← links)
- Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data (Q33994633) (← links)
- Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy (Q34051790) (← links)
- SPHK1 regulates proliferation and survival responses in triple-negative breast cancer (Q34227524) (← links)
- PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (Q34296476) (← links)
- Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis (Q34328227) (← links)
- Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data (Q34560725) (← links)
- ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy (Q35051318) (← links)
- Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (Q35237197) (← links)
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis (Q35558914) (← links)
- Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients (Q35651216) (← links)
- Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer (Q35803370) (← links)
- Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China (Q35909551) (← links)
- Pathological complete response in younger and older breast cancer patients (Q35990463) (← links)
- Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer (Q36092026) (← links)
- ALK alteration is a frequent event in aggressive breast cancers. (Q36105958) (← links)
- Triple negative breast cancer - prognostic factors and survival (Q36177748) (← links)
- Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death (Q36306513) (← links)
- Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors (Q36649503) (← links)
- Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. (Q36924445) (← links)
- Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses (Q37113312) (← links)
- Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. (Q37180350) (← links)
- Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. (Q37319292) (← links)
- Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women (Q37356185) (← links)
- Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy (Q37547957) (← links)
- Pharmacotherapy of triple-negative breast cancer (Q37565645) (← links)
- A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy (Q37662215) (← links)
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (Q37809456) (← links)
- Adjuvant systemic treatment for individual patients with triple negative breast cancer (Q37947894) (← links)
- Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. (Q38047337) (← links)
- Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size (Q38420000) (← links)
- Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer (Q38451966) (← links)
- 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study (Q38458792) (← links)
- Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression (Q38461102) (← links)
- Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy (Q38465537) (← links)
- Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy (Q38465712) (← links)
- Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines. (Q38766037) (← links)
- Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis (Q38770344) (← links)
- Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer (Q41722410) (← links)
- Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer (Q42117291) (← links)
- Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy (Q42458534) (← links)